Home » Newsletters » BioWorld Science

BioWorld Science

June 25, 2004

View Archived Issues

Transgene highlights first quarter developments

Broad antitumor activity reported for Veglin in vivo

Orally active small molecule erythropoietic agent for the treatment of anemia

Panitumumab demonstrates encouraging antitumor activity

Bevacizumab demonstrates substantial clinical activity

Green tea extract may reverse tetracycline resistance

Metabolic conversion of anticancer agent SD-2007 to apicidin in rats

Topical tacrolimus found to improve skin lesions in patients with connective tissue disease

Remicade approved in E.U. for early rheumatoid arthritis

North American phase III trial initiated for Alzhemed

New European approval for Herceptin

Good safety profile reported for AP-23573 in patients with refractory tumors

Exanta launched in Germany

FDA lifts clinical hold on phase I NHL study of PPI-2458

GPI-0100 to be studied by Memorial Sloan-Kettering under new agreement

New trials to expand StaphVAX potential beyond ERSD patients

Liarozole receives U.S. orphan drug status for congenital ichthyosis

Immusol initiates collaboration with Affymetrix for oncology drug discovery

XenoPort presents new gemcitabine prodrugs

Novel HCV NS5B inhibitors jointly reported by ViroPharma and Wyeth

Roche claims two series of protein kinase inhibitors for use in cancer therapy

Three series of orexin antagonists patented by GSK researchers

New antibacterial agents covered by GSK patent

New antitumor agents developed by Sanofi-Synthelabo scientists

Mepolizumab reduces allergen-induced eosinophils and tenascin deposition

R-483 studied in animal models, diabetic patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.